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Background: Chronic kidney disease (CKD) is a consequence of progressive and irreversible 
destruction of nephrons, mainly due to uncontrolled diabetes mellitus and high blood 
pressure. Ghrelin is a peptide hormone which could play a substantial role in hunger 
sensation, may increase body fat percentage and might adjust the long-term body weight 
and is mostly secreted in the stomach. 
Objectives: This study aimed to evaluate the relationship between ghrelin levels and various 
biochemical and demographic indices in a group of non-diabetic hemodialysis patients. 
Patients and Methods: Around 39 non-diabetic patients undergoing hemodialysis in Hajar 
hospital at Shahrekord city were enrolled.
Results: The mean age of patients was 57.10 ± 20.20 years. Their mean weight was 56.65 
±16.25 kg. Their hemoglobin level mean was 10.43 ± 1.84 g/dL. The serum ghrelin level 
had a positive but not significant correlation with the age, dialysis quality, dosage, calcium 
level, alkaline phosphatase (ALP), parathormone, vitamin D and hemoglobin in these 
patients. 
Conclusions: More studies in this subject of hemodialysis patients to define the exact role of 
ghrelin in hemodialysis patients are recommended.
ABSTRACT
Implication for health policy/practice/research/medical education:
In a study on 39 non-diabetic patients undergoing hemodialysis, we found that serum ghrelin level had a positive but not 
significant correlation with the age, dialysis quality, dosage, calcium level, alkaline phosphatase (ALP), parathormone, vitamin 
D and hemoglobin in these patients.
Please cite this paper as: Mahmoodnia L, Beigrezaei S, Tamadon MR, Jafari T, Kafeshani M, Mahmoodi F, et al. The relationship 
between serum ghrelin levels and bone metabolism markers and severity anemia in non-diabetic hemodialysis patients; a pilot 
study. J Nephropathol. 2018;7(1):32-36. DOI: 10.15171/jnp.2017.10.
1. Background
Chronic kidney disease (CKD) is a consequence of 
progressive and irreversible destruction of  nephrons, 
mainly due to uncontrolled diabetes mellitus and high 
blood pressure (1). The prevalence rate of  this disease is 
increasing worldwide about 8% annually (2,3). In addition, 
end-stage renal disease (ESRD) would be the final stage of 
CKD, when the patient needs an alternative method such 
as dialysis. Moreover, the annual mortality rate of  dialysis 
patients is around 15%-20% and their 5-year survival rate 
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is 30%-35% (1). However, cardiovascular and infectious 
diseases could be the chief  causes of  death among these 
patients (1,4). Therefore, the identification and prevention 
of  these diseases and potential increase of  life expectancy 
of  dialysis patients are very important. 
Ghrelin is a peptide hormone which could be playing 
a substantial role in hunger sensation, increasing body 
fat percentage and adjusting the long-term body weight 
and is mostly secreted in the stomach (5-7). Additionally, 
other parts of  gastrointestinal tract, especially the small 
intestine, pancreas epsilon cells, kidney glomerular cells, 
hypothalamus neurons and hypophysis are also able to 
secrete this hormone (8). The importance of  ghrelin 
in CKD is notable from many aspects. For example, 
the role of  ghrelin in energy balance and reduction of 
insulin resistance has been widely recognized (9-11). 
Thus, measuring blood ghrelin level and determining 
its relationship with other important factors provide 
some valuable information about the role of  ghrelin in 
the pathophysiology of  various diseases such as type 2 
diabetes, which is the main cause of  chronic kidney failure 
(9). Moreover, with the decrease of  kidney function, the 
ghrelin serum level may increase, up to 2-3 times higher 
in patients suffering from stage five of  chronic kidney 
failure compared to healthy individuals emphasizing the 
important role of  kidneys in the destruction of  ghrelin 
(12-14). The high blood levels of  ghrelin could entail the 
increase in the micro- and macro-vascular complications 
which may lead to ESRD (14). Chang et al demonstrated 
that high ghrelin levels could be an important risk factor 
for cardiovascular disease (15). Therefore, the increase in 
ghrelin levels in dialysis patients may contribute to various 
complications and increasing mortality rates in this group. 
Ayala et al reported a significant relationship between the 
baseline serum levels of  ghrelin and serum insulin levels, 
body mass index (BMI), abdominal fat and serum leptin 
levels (16). Furthermore, Isguven et al studied ghrelin 
levels in children suffering from anemia and reported 
that ghrelin level was significantly lower than normal 
individuals (17). In another study on menopausal women, 
the serum ghrelin levels were found to be lower than 
non-menopausal healthy individuals with a significant 
relationship between serum ghrelin and bone density (18).
2. Objectives
Despite numerous studies supporting the notion of 
increased serum levels of  ghrelin in hemodialysis patients, 
there is not enough information regarding the relationship 
between ghrelin and various metabolic factors such 
as vitamin D or inflammatory factors like C-reactive 
protein (CRP) and anemia. The aim of  this study was 
the evaluation of  the relationship between serum ghrelin 
levels with various biochemical and demographic indices 
in a group of  non-diabetic hemodialysis patients.
3. Patients and Methods 
3.1. Study population
In this cross-sectional study, 40 hemodialysis patients of 
Hajar hospital at Shahrekord were studied in 2015. As one 
of  the patients withdrew from the study, 39 patients were 
studied. The study consisted of  non-diabetic patients 
undergoing hemodialysis. 
3.2. Laboratory assessments
A fasting time of  about 8 hours, venous blood samples 
were obtained for biochemical measurements including 
ghrelin, calcium, phosphorus, vitamin D, alkaline 
phosphatase (ALP), and intact parathyroid hormone 
(PTH), C-reactive protein (CRP) and also hemoglobin 
levels. Ghrelin was measured by Demeditec Diagnostics 
kit (Germany) with ELISA method (7).
3.3. Demographic information
To obtain these data, we used a questionnaire including 
demographic information such as age, gender, the 
duration of  dialysis and BMI. BMI can be calculated by 
dividing the weight in kilograms to the square root of  the 
height in meters. To calculate the dialysis adequacy we 
applied urea reduction ratio (URR).
3.4. Ethical issues
1) The research followed the tenets of  the Declaration 
of  Helsinki; 2) informed consent was obtained; and 3) 
This study was approved by the Ethics Committee of 
Shahrekord University of  Medical Sciences (ethical code# 
lRskums.Rec.1394.272).
3.5. Statistical analysis
For analysis, we applied SPSS software version 20. For 
correlation, Spearman’s test was used and P values of  less 
than 0.05 were regarded as statistically significant.
4. Results
The mean age of  the patients was 57.10± 20.20 years. Their 
mean weight was 56.65± 16.25 kg. Their hemoglobin level 
mean was 10.43 ± 1.84 g/dL.
Table 1 shows the results of  biochemical, clinical and 
anthropometrical measurements of  patients. The mean 
ghrelin level of  non-diabetic hemodialysis patients was 
5.62± 4.61 ng/mL (median; 3.25 ng/mL).
In addition, we found that the serum ghrelin level had 
a positive correlation but not significant with the age, 
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dialysis quality, dosage, calcium level, ALP, parathormone, 
vitamin D and hemoglobin in these patients. It should be 
noted that there was no significant association between 
serum ghrelin level and other factors (P > 0.05). Ghrelin 
serum level was negatively correlated with phosphorus 
level, but the correlation was not significant too (P > 0.05) 
(Table 2).
Ghrelin level was not significantly correlated with gender 
(27 men and 13 women), CRP and vitamin D in patients 
(P > 0.05) (Table 3).
5. Discussion
Kidneys play an important role in the biodegradation 
and removing the ghrelin in blood circulation (19). In 
fact, when the function of  kidneys is decreasing, the 
serum ghrelin level will increase, which reflects the critical 
role of  kidneys in biodegradation of  ghrelin (12-14). 
In addition, due to the raised ghrelin levels in patients 
suffering from kidney failure, and the negative impacts 
of  high ghrelin levels on the dialysis prognosis and their 
quality of  life, investigating the factors impacting on the 
association of  ghrelin levels and these problems seems to 
be necessary in order to find a way to reduce ghrelin levels 
and consequently reducing the dialysis complications 
and costs. This study was conducted to investigate the 
relationship between serum ghrelin level and bone 
Table 1. Biochemical, clinical and anthropometrical data of  non-
diabetic hemodialysis patients (n = 39)
Factor Median Mean± SD
Age (y) 62 57.10 ± 20.20
Weight (kg) 53.25 56.65 ± 16.25
Calcium, mg/dL 9.1 9.15± 1.18
Phosphorus, mg/dL 6.0 5.96± 0.85
Hemoglobin, g/dL 10.55 10.43± 1.84
URR, % 71 72.30± 6.53
ALP, IU/mL 502.5 528.53± 283.81
Intact PTH, pg/mL 637.95 807.03± 686.86
Vitamin D, ng/mL 20.25 22.64± 11.32
Ghrelin, ng/mL 3.25 5.62± 4.61
Dialysis dosage 960 2000.00± 2249.77
Dialysis duration, months 24 44.7± 50.92
Abbreviations: URR, urea reduction ratio; ALP, alkaline 
phosphatase; PTH, Parathyroid hormone.
Table 2. Correlation between the ghrelin level and the studied factors in non-diabetic hemodialysis factors
Ghrelin Age (y)
URR
(%)
Duration 
of  dialysis* 
(mon)
Dialysis 
dosage
Calcium
(mg/dL)
Phosphorus
(mg/dL)
Hemoglobin
(g/dL)
ALP
(IU/
mL)
PTH 
(pg/mL)
Vitamin D 
(ng/mL)
Ghrelin 1 0.19 0.25 0.14* 0.15 -0.67 -0.009 0.02 -0.2 -0.019 0.09
P value - 0.23 0.11 0.38 0.34 0.68 0.96 0.90 0.9 0.91 0.58
*The dialysis duration from the beginning.
metabolism factors, inflammation, and anemia severity in 
non-diabetic hemodialysis patients.
Our study showed that serum ghrelin levels had a positive 
but not significant correlation with the age, dialysis quality, 
dosage, calcium level, ALP, parathormone, vitamin D and 
hemoglobin in non-diabetic hemodialysis patients. The 
correlation between ghrelin level and dialysis duration was 
positive but not significant. The serum ghrelin level was 
shown to be negatively correlated with phosphate level, 
however it was not significant as well as CRP and gender.
Moreover, studies have shown that ghrelin levels in 
hemodialysis patients are significantly higher than 
healthy individuals. For example, Pérez-Fontán et al 
reported higher ghrelin plasma levels in patients receiving 
hemodialysis and peritoneal dialysis compared to the 
control group (13). Chang et al have also demonstrated 
that ghrelin levels are higher in ESRD patients compared 
to the control group (15). In addition, Firczyk et al found 
that the average ghrelin plasma level in healthy individuals, 
the hemodialysis group with diabetic nephropathy and 
hemodialysis patients without diabetic nephropathy 
were 4.33, 6.47, and 5.78 ng/mL, respectively, which is 
significantly higher than that of  the healthy control group 
(19). In our study, the mean ghrelin level of  non-diabetic 
hemodialysis patients was 5.62± 4.61 ng/mL which is 
similar to their study.
Izadi et al also reported that there was a direct linear 
relationship between serum ghrelin levels and the BMI 
of  patients, but this correlation was not statistically 
significant (9). Our study showed the positive but not 
significant correlation between ghrelin level and age 
of  non-diabetic hemodialysis as well. On the contrary, 
Katsuki et al observed lower levels of  plasma ghrelin in 
obese patients suffering from diabetes mellitus type 2 
compared to non-obese patients and argued for a negative 
significant correlation between ghrelin serum levels and 
BMI (20). In addition, in the study of  Farajallah et al, 
lower ghrelin levels were observed in diabetic insulin 
resistant patients (21) which might be accounted for the 
negative correlation between the ghrelin levels and insulin 
levels of  these patients.
In this study, the duration of  dialysis was 44.7± 50.92 
months. There was a positive but not significant association 
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between the serum ghrelin levels and duration of  dialysis 
in non-diabetic patients. In the study of  Firczyk et al, 
the average duration of  hemodialysis in the hemodialysis 
with diabetic nephropathy group was 28 months and in 
the hemodialysis patients without nephropathy was 25 
months (19).
Furthermore, in the study by Isguven et al in 2007, among 
the children suffering from iron deficiency anemia, the 
ghrelin levels were significantly lower than the control 
group, but no clear association between the ghrelin levels 
and their blood parameters was found (17). In our study, 
the ghrelin levels of  non-diabetic hemodialysis patients 
showed a positive and not significant correlation with 
their hemoglobin levels.
Similar to our study, Izadi et al also observed a positive 
but not significant correlation between ghrelin and 
hemoglobin level (9).
In the recent decades, the probability of  vitamin D 
deficiency in type 2 diabetic patients and the serum levels 
of  25-hydroxy vitamin D was considered as the predictive 
factors of  long-term complications of  diabetes, such as 
cardiovascular diseases. For instance, Rahimi et al found, 
among diabetic patients, 82.2% of  them suffered from 
vitamin D deficiency compared to 61.1% in healthy 
individuals. They have also reported lower levels of 
vitamin D in overweight individuals compared to those 
who were normal weight and healthy (22). In our study, 
the vitamin D level in non-diabetic hemodialysis patients 
was 22.64± 11.32 ng/mL and their mean phosphorus level 
was 5.96± 0.85 mg/dl. We found a negative not significant 
correlation between serum ghrelin and phosphorus levels 
in these patients.
Moreover, Rahimi et al demonstrated the mean ALP in 
diabetic patients to be 195.2 ± 54.5 IU/ml and in non-
diabetics to be 181.9 ± 55.7 IU/ml (22), but in our study 
the mean level of  ALP for non-diabetic hemodialysis 
patients was 528.53 ± 283.81 IU/mL. We may account 
these differences between various studies into the 
difference in the sample sizes. Therefore, the comparison 
of  the findings of  studies with a bigger population and 
more dispersion among the population might result in 
better and more reliable results.
In the studies carried out on chronic obstructive pulmonary 
diseases (COPD) patients, a negative correlation between 
Table 3. The correlations between ghrelin level and gender, serum 
CRP and vitamin D levels in non-diabetic hemodialysis patients
Gender CRP Vitamin D level
Ghrelin Male (n = 27) 1 1
Female (n = 13) 2 2
P value >0.05 >0.05 >0.05
the ghrelin levels and CRP levels was observed (23). 
However, Barros et al reported that the serum ghrelin 
levels were significantly higher in hemodialysis patients, 
but no significant correlation was found between the 
inflammatory and ghrelin factors (24). In addition, in a 
study on menopause women, no significant association 
between the ghrelin levels and ALP was observed (18,25).
6. Conclusions
In this study, serum ghrelin level had a positive but 
not significant correlation with the age, dialysis quality, 
dosage, calcium level, ALP, parathormone, vitamin D and 
hemoglobin levels in non-diabetic hemodialysis patients. 
More studies in this area are recommended.
Limitations of  the study
One of  the limitations of  this study was its small sample 
size. Thus, in order to increase the replicability of  this 
study, we suggest further studies with larger sample sizes. 
We also recommend that other studies be done with the 
aim of  determining serum ghrelin level and its association 
with different blood and biochemical factors in various 
populations, based on their gender, age groups as well as 
investigating the association between ghrelin serum level 
with blood fat levels in non-diabetic hemodialysis patients 
and comparing them with those of  the healthy population.
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